We found that Nilotinib treatment of LN18 and LN229 GBM cells, in which ABL is expressed and constitutively activated, also resulted in the acquisition of a mesenchymal-like morphology (Supplementary Figure S4A and S4B) accompanied by changes in levels of some epithelial (Cytokeratin-18, Syndecan-3, ZEB-1) and mesenchymal (SNAIL, CD44; VIMENTIN as well for LN229 cells) markers (Supplementary Figure S4C-S4F). Here, KRT18 is linked to glioblastoma.